Alex Zhavoronkov, Founder, CEO & CBO of Insilico Medicine, says the Takeda deal lets the company scale beyond its own ...

The deal could include further milestone payments, potentially bringing the total value to approximately $600m.

Insilico Medicine said Thursday it entered into a strategic collaboration with Takeda Pharmaceutical Co. Ltd. to use its ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Takeda will pay Insilico to use its proprietary Pharma.AI platform to advance drug candidates across several therapeutic ...

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland, on July 7.

Cambridge, MA, Sept. 26, 2024 –Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced today that Fierce Life Sciences and Fierce Healthcare have named Insilico ...

CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration ...

A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory ...

Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, ...